Baystate Wealth Management’s Arcus Biosciences RCUS Stock Holding History

Baystate Wealth Management’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2	Closed	–	–	745
2020 Q3	$0	Buy	+2	New	+$45	﹤0.01%	724

Other funds holding RCUS

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baystate Wealth Management's RCUS Position: Q4 2020 in Review

Baystate Wealth Management sold out of Arcus Biosciences (RCUS) in Q4 2020, closing a stake of 2 shares.

Baystate Wealth Management first reported a position in RCUS in Q3 2020 and held it in 1 quarter. The position peaked at $0 in Q3 2020. 148 funds tracked by Wall St. Rank hold RCUS as of Q4 2020.

Baystate Wealth Management reported no remaining Arcus Biosciences position as of Q4 2020 after selling out during the quarter.
Baystate Wealth Management sold 2 Arcus Biosciences shares in Q4 2020.
Baystate Wealth Management first reported a position in Arcus Biosciences in Q3 2020 and held it in 1 quarter.
Baystate Wealth Management's Arcus Biosciences position peaked at $0 in Q3 2020.
148 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2020.

Based on Baystate Wealth Management's 13F filing for Q4 2020, filed 15 Jan 2021.